TCM
SUPN icon

Tributary Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Tributary Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-308,587
Closed -$9.73M – 174
2025
Q2 		$9.73M Sell
308,587
-23,392
-7% -$750K 0.86% 58
2025
Q1 		$10.9M Sell
331,979
-11,983
-3% -$425K 0.95% 55
2024
Q4 		$12.4M Sell
343,962
-357
-0.1% -$12.6K 0.96% 56
2024
Q3 		$10.7M Sell
344,319
-802
-0.2% -$25K 0.83% 55
2024
Q2 		$9.23M Buy
345,121
+283
+0.1% +$8.2K 0.77% 58
2024
Q1 		$11.8M Sell
344,838
-1,423
-0.4% -$42.4K 0.96% 54
2023
Q4 		$10M Sell
346,261
-6,168
-2% -$164K 0.84% 60
2023
Q3 		$9.72M Buy
352,429
+4,189
+1% +$128K 0.92% 59
2023
Q2 		$10.5M Sell
348,240
-5,431
-2% -$190K 0.94% 55
2023
Q1 		$12.8M Buy
353,671
+11,445
+3% +$440K 1.19% 42
2022
Q4 		$12.2M Sell
342,226
-12,798
-4% -$445K 1.22% 44
2022
Q3 		$12M Sell
355,024
-5,459
-2% -$178K 1.26% 39
2022
Q2 		$10.4M Buy
360,483
+23,637
+7% +$677K 1.04% 51
2022
Q1 		$10.9M Buy
336,846
+16,104
+5% +$494K 0.86% 57
2021
Q4 		$9.35M Sell
320,742
-19,875
-6% -$603K 0.71% 62
2021
Q3 		$9.08M Buy
340,617
+39,478
+13% +$1.06M 0.7% 63
2021
Q2 		$9.27M Sell
301,139
-14,102
-4% -$432K 0.7% 60
2021
Q1 		$8.25M Buy
+315,241
New +$8.82M 0.64% 60

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tributary Capital Management's SUPN Position: Q3 2025 in Review

Tributary Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 308,587 shares — an estimated $9.73M sold.

Tributary Capital Management first reported a position in SUPN in Q1 2021 and held it in 18 quarters. The position peaked at $12.8M in Q1 2023. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Tributary Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Tributary Capital Management sold 308,587 Supernus Pharmaceuticals shares in Q3 2025, an estimated $9.73M.
  • Tributary Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 18 quarters.
  • Tributary Capital Management's Supernus Pharmaceuticals position peaked at $12.8M in Q1 2023.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Tributary Capital Management's 13F filing for Q3 2025, filed 23 Oct 2025.